AR and prostate cancer: Together with the roles of AR/TGF-β signaling in prostate cancer progression, it was hypothesized that PMEPA1 functions as a biologically significant candidate biomarker for monitoring prostate cancer aggressiveness including metastases and CRPC, as well as for the evaluation of metastasis-free survival.